Indevus Pharmaceuticals (IDEV) Misses Q4 EPS by 2c
More News related to IDEV
- Endo Pharma (ENDP) Extends Period of Tender Offer for Shares of Indevus (IDEV)
- Indevus Pharma (IDEV) Announces NIH-Sponsored Study on PRO 2000 Shows Promise in HIV Prevention
- JMP Downgrades Indevus Pharma (IDEV) to Market Perform
- UBS Downgrades Indevus Pharmaceuticals (IDEV) to Neutral
- Unusual 11 Mid-Day Movers 1/6: IDEV, TXCO, ARM, ALD Higher; VDSI, CTDC, SMCI, ENDP Lower
More News related to Earnings
- Denison Mines (DNN) Posts Q3 Loss of $0.27, Misses Views
- RailAmerica (RA) Reports Q3 EPS of $0.08
- Western Gas Partners (WES) Posts Q3 EPS of $0.30, Beats by 3c
- Kongzhong (KONG) Posts Q3 non-GAAP EPS of $0.16, Tops by 6c
- Applied Materials (AMAT) Post Better Than Expected Profit, But To Show 1,500 Workers The Door
Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) reports a Q4 loss of $0.25, 2 cents worse than estimates. Revenues were $15.2 million vs. $11.55 million consensus.
Total consolidated revenues during fiscal 2006 were $50.5 million, an increase of 51% from fiscal 2005 revenues of $33.3 million. Fiscal 2006 revenue consisted primarily of $15.0 million of revenues received in connection from product sales of SANCTURA to the Company's partner, $13.4 million from the amortization of upfront and milestone revenue for SANCTURA received from the Company's partner, $7.7 million of SANCTURA royalties, $8.8 million in sales force subsidy and $2.7 million from net sales of DELATESTRYL.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
